Coherus BioSciences, Inc. (CHRS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

12/25

Growth 4 Margin 3 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

12
Coherus BioSciences (CHRS) Q2 2026: Loctorsi Eyes $15M Quarter as SG&A Drops for Sixth Straight Period
August 06, 2026
13
Coherus Oncology (CHRS) Q1 2026: Lactorsi New Patient Starts Jump 21% as Pipeline Readouts Approach
June 17, 2026
12
Coherus Oncology (CHRS) Q2 2025: Lactorzy Revenue Jumps 36% as Pipeline Readouts Near
June 16, 2026
9
Coherence Oncology (CHRS) Q3 2025: Lactorsi Demand Up 92% YoY, Pipeline Data Readouts Set for 2026
June 16, 2026
12
Coherus (CHRS) Q4 2025: Lactorsi Revenue Doubles, Funding 70% Market Share Push
June 15, 2026
13
Coherus BioSciences (CHRS) Q1 2025: LOQTORZI Demand Grows 15% Amid Strategic Oncology Focus
May 12, 2025
Coherus BioSciences (CHRS) Q4 2024: UDENYCA Divestiture Sets Stage for $250M Cash Runway and Oncology Focus
March 10, 2025

Browse all companies